Published in Lab Law Weekly, June 1st, 2007
Intrexon president and chief executive Robert Beech said the investment should allow the privately held company to grow to roughly three times its current size, or about 130 employees by the end of this year.
The bulk of those employees will likely do research and development associated with Intrexon's pre-clinical studies in gene-based therapy.
The company develops new ways to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.